{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T12:41:52Z","timestamp":1648730512843},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1007\/s00120-013-3253-y","type":"journal-article","created":{"date-parts":[[2013,11,6]],"date-time":"2013-11-06T16:37:49Z","timestamp":1383755869000},"page":"1564-1573","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Tumortherapie urogenitaler Malignome"],"prefix":"10.1007","volume":"52","author":[{"given":"A.","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Krege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,8]]},"reference":[{"key":"3253_CR1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.eururo.2011.05.038","volume":"60","author":"Albers","year":"2011","unstructured":"Albers P, Albrecht W, Algaba F et al (2011) Guidelines on testicular cancer. 2001 Update. Eur Urol 60:304\u2013319","journal-title":"Eur Urol"},{"key":"3253_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","volume":"59","author":"Heidenreich","year":"2011","unstructured":"Heidenreich A, Bellmunt J, Bolla M et al (2011) Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59(1):61\u201371","journal-title":"Eur Urol"},{"key":"3253_CR3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","volume":"59","author":"Mottet","year":"2011","unstructured":"Mottet N, Bellmunt J, Bolla M et al (2011) Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572\u2013583","journal-title":"Eur Urol"},{"key":"3253_CR4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","volume":"58","author":"Ljungberg","year":"2010","unstructured":"Ljungberg B, Cowan NC, Hanbury DC et al (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58(3):398\u2013406","journal-title":"Eur Urol"},{"key":"3253_CR5","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009\u20131018","journal-title":"Eur Urol"},{"key":"3253_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3253_CR7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1148\/radiol.2391050343","volume":"239","author":"Winer-Muram","year":"2006","unstructured":"Winer-Muram HT (2006) The solitary pulmonary nodule. Radiology 239:34\u201349","journal-title":"Radiology"},{"key":"3253_CR8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00330-004-2527-6","volume":"15","author":"Wormanns","year":"2005","unstructured":"Wormanns D, Ludwig K, Beyer F et al (2005) Detection of pulmonary nodules at multirow-detector CT: effectiveness of double reading to improve sensitivity at standard-dose and low-dose chest CT. Eur Radiol 15:14\u201322","journal-title":"Eur Radiol"},{"key":"3253_CR9","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2214\/AJR.04.0814","volume":"185","author":"Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der T, R\u00fchm SG, Debatin JF et al (2005) Detection of pulmonary nodules using 2D HASTE MR sequence: comparison with MDCT. AJR Am J Roentgenol 185:979\u2013984","journal-title":"AJR Am J Roentgenol"},{"key":"3253_CR10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1102\/1470-7330.2008.0009","volume":"8","author":"Fujimoto","year":"2008","unstructured":"Fujimoto K (2008) Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer Imaging 8:36\u201344","journal-title":"Cancer Imaging"},{"key":"3253_CR11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/00004728-200411000-00007","volume":"28","author":"Kim","year":"2004","unstructured":"Kim JH, Kim HJ, Lee KH et al (2004) Solitary pulmonary nodules: a comparative study evaluated with contrast-enhanced dynamic MR imaging and CT. J Comput Assist Tomogr 28:766\u2013775","journal-title":"J Comput Assist Tomogr"},{"key":"3253_CR12","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejrad.2005.11.041","volume":"58","author":"Kanematsu","year":"2006","unstructured":"Kanematsu M, Kondo H, Goshima S et al (2006) Imaging liver metastases: review and update. Eur J Radiol 58:217\u2013228","journal-title":"Eur J Radiol"},{"key":"3253_CR13","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3748\/wjg.15.4327","volume":"15","author":"Khan","year":"2009","unstructured":"Khan SA (2009) Imaging of liver cancer. World J Gastroenterol 15:1289\u20131300","journal-title":"World J Gastroenterol"},{"key":"3253_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/rmr.0b013e3181614374","volume":"18","author":"Ba-Ssalamah","year":"2007","unstructured":"Ba-Ssalamah A, Fakhrai N, Matzek WK et al (2007) Magnetic resonance imaging of liver malignancies. Top Magn Reson Imaging 18:445\u2013455","journal-title":"Top Magn Reson Imaging"},{"key":"3253_CR15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/cmmi.116","volume":"1","author":"Barrett","year":"2006","unstructured":"Barrett T, Choyke PL, Kobayashi H (2006) Imaging of the lymphatic system: new horizons. Contrast Media Mol Imaging 1:230\u2013245","journal-title":"Contrast Media Mol Imaging"},{"key":"3253_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1055\/s-1999-256","volume":"171","author":"Krug","year":"1999","unstructured":"Krug B, Heidenreich A, Dietlein M et al (1999) Lymphknotenstaging maligner testikul\u00e4rer Keimzelltumoren. Fortschr R\u00f6ntgenstr 171:87\u201394","journal-title":"Fortschr R\u00f6ntgenstr"},{"key":"3253_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00261-005-0244-5","volume":"31","author":"Morisawa","year":"2006","unstructured":"Morisawa N, Koyama T, Togashi K (2006) Metastatic lymph nodes in urogenital cancers: contribution of imaging findings. Abdom Imaging 31:620\u2013629","journal-title":"Abdom Imaging"},{"key":"3253_CR18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00261-001-0182-9","volume":"28","author":"Bellin","year":"2003","unstructured":"Bellin MF, Lebleu L, Meric JB (2003) Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MRI lymphangiography. Abdom Imaging 28:155\u2013163","journal-title":"Abdom Imaging"},{"key":"3253_CR19","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/CBM-2009-0578","volume":"5","author":"Islam","year":"2009","unstructured":"Islam T, Harisinghani MG (2009) Overview of nanoparticle use in cancer imaging. Cancer Biomark 5:61\u201367","journal-title":"Cancer Biomark"},{"key":"3253_CR20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.eururo.2007.01.061","volume":"51","author":"Powles","year":"2007","unstructured":"Powles T, Murray I, Brock C et al (2007) Molecular positron emission tomography and PET\/CT imaging in urological malignancies. Eur Urol 51:1511\u20131521","journal-title":"Eur Urol"},{"key":"3253_CR21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1148\/121.2.431","volume":"121","author":"Schaffer","year":"1976","unstructured":"Schaffer Dl, Pendergrass HP (1976) Comparison of enzyme, clinical, radiographic and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 121:431\u2013434","journal-title":"Radiology"},{"key":"3253_CR22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-5347(17)54979-4","volume":"125","author":"Pollen","year":"1981","unstructured":"Pollen JJ, Gerber K, Ashburn WL, Schmidt JD (1981) The value of nuclear bone imaging in advanced prostate cancer. J Urol 125:222\u2013233","journal-title":"J Urol"},{"key":"3253_CR23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejrad.2005.01.016","volume":"55","author":"Ghanem","year":"2005","unstructured":"Ghanem N, Uhl M, Brink I et al (2005) Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET\/CT for the detection of metastases of bone. Eur J Radiol 55:41\u201355","journal-title":"Eur J Radiol"},{"key":"3253_CR24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2463\/mrms.6.147","volume":"6","author":"Nakanishi","year":"2007","unstructured":"Nakanishi K, Kobayashi M, Nakaguchi K et al (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 6:147\u2013155","journal-title":"Magn Reson Med Sci"},{"key":"3253_CR25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.rli.0000149250.37033.7c","volume":"40","author":"Schlemmer","year":"2005","unstructured":"Schlemmer HP, Sch\u00e4fer J, Pfannenberg C et al (2005) Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol 40:64\u201371","journal-title":"Invest Radiol"},{"key":"3253_CR26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejrad.2005.01.019","volume":"55","author":"Schmidt","year":"2005","unstructured":"Schmidt GP, Schoenberg SO, Reiser MF, Baur-Malnyk A (2005) Whole-body MR imaging of bone marrow. Eur J Radiol 55:33\u201340","journal-title":"Eur J Radiol"},{"key":"3253_CR27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/pros.20280","volume":"65","author":"Tombal","year":"2005","unstructured":"Tombal B, Rezazadeh A, Therasse P et al (2005) Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 65:178\u2013187","journal-title":"Prostate"},{"key":"3253_CR28","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1200\/JCO.2006.09.2940","volume":"25","author":"Lecouvet","year":"2007","unstructured":"Lecouvet FE, Geukens D, Stainier A et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25:3281\u20133287","journal-title":"J Clin Oncol"},{"key":"3253_CR29","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00330-006-0361-8","volume":"17","author":"Schmidt","year":"2007","unstructured":"Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939\u2013949","journal-title":"Eur Radiol"},{"key":"3253_CR30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2007.12.025","volume":"53","author":"Krege","year":"2008","unstructured":"Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol 53:497\u2013513","journal-title":"Eur Urol"},{"key":"3253_CR31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.crad.2008.10.011","volume":"64","author":"Sohaib","year":"2009","unstructured":"Sohaib SA, Koh DM, Barbachano Y et al (2009) Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol 64(4):362\u2013367","journal-title":"Clin Radiol"},{"key":"3253_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2007.10.033","volume":"53","author":"Heidenreich","year":"2008","unstructured":"Heidenreich A, Th\u00fcer D, Polyakov S (2008) Postchemotherapy retroperitoneal lymph node dissection in advanced germ cell tumours of the testis. Eur Urol 53:260\u2013272","journal-title":"Eur Urol"},{"key":"3253_CR33","first-page":"120","volume":"8","author":"Akbulut","year":"2011","unstructured":"Akbulut Z, Canda AE, Atmaca AF et al (2011) Is positron emission tomography reliable to predict post-chemotherapy retroperitoneal lymph node involvement in advanced germ cell tumors of the testis? Urol J Spring 8(2):120\u2013126","journal-title":"Urol J Spring"},{"key":"3253_CR34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mdr052","volume":"23","author":"Bachner","year":"2012","unstructured":"Bachner M, Loriot Y, Gross-Goupil M et al (2012) 2\u201318fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 23:59\u201364","journal-title":"Ann Oncol"},{"key":"3253_CR35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eururo.2010.09.004","volume":"59","author":"Picchio","year":"2011","unstructured":"Picchio M, Briganti A, Fanti S et al (2011) The role of choline positron emission tomography\/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59(1):51\u201360","journal-title":"Eur Urol"},{"key":"3253_CR36","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"Bono","year":"2011","unstructured":"Bono JS de, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995\u20132005","journal-title":"N Engl J Med"},{"key":"3253_CR37","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983\u2013992","journal-title":"Lancet Oncol"},{"key":"3253_CR38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F et al (2012) Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. N Engl J Med 367:1187\u20131197","journal-title":"N Engl J Med"},{"key":"3253_CR39","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol"},{"key":"3253_CR40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1464-410X.2003.04362.x","volume":"92","author":"Yahara","year":"2003","unstructured":"Yahara J, Noguchi M, Noda S (2003) Quantitative evaluation of bone metastases in patients with advanced prostate cancer during systemic treatment. BJU Int 92:379\u2013384","journal-title":"BJU Int"},{"key":"3253_CR41","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00259-005-1843-7","volume":"32","author":"Garc\u00eda","year":"2005","unstructured":"Garc\u00eda JR, Sim\u00f3 M, Soler M et al (2005) Relative roles of bone scintigraphy and positron emission tomography in assessing the treatment response of bone metastases. Eur J Nucl Med Mol Imaging 32:1243\u20131244","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3253_CR42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","volume":"247","author":"Tateishi","year":"2008","unstructured":"Tateishi U, Gamez C, Dawood S et al (2008) Bone metastases in patients with metastatic breast cancer. Morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT. Radiology 247:189\u2013196","journal-title":"Radiology"},{"key":"3253_CR43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/MNM.0b013e328313b7bc","volume":"30","author":"Lindholm","year":"2009","unstructured":"Lindholm P, Lapely M, Nagren K et al (2009) Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun 30:30\u201336","journal-title":"Nucl Med Commun"},{"key":"3253_CR44","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1076-6332(03)80461-0","volume":"9","author":"Stafford","year":"2002","unstructured":"Stafford SE, Gralow JR, Schubert EK et al (2002) Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9:913\u2013921","journal-title":"Acad Radiol"},{"key":"3253_CR45","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00259-008-0788-z","volume":"35","author":"Beheshti","year":"2008","unstructured":"Beheshti M, Vali R, Waldenberger P et al (2008) Detection of bone metastases in patients with prostate cancer by F-18 fluorocholine and F-18 fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 35:1766\u20131774","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3253_CR46","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.2214\/AJR.09.3456","volume":"194","author":"Smith","year":"2010","unstructured":"Smith AD, Shah SN, Rini BI et al (2010) Morphology, attentuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194:1470\u20131478","journal-title":"AJR Am J Roentgenol"},{"key":"3253_CR47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2214\/AJR.11.7483","volume":"198","author":"Nishino","year":"2012","unstructured":"Nishino M, Jagannathan JP, Krajewski KM et al (2012) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737\u2013745","journal-title":"AJR Am J Roentgenol"},{"key":"3253_CR48","doi-asserted-by":"crossref","unstructured":"Braunagel M, Graser A, Reiser M et al (2013) The role of functional imaging in the era of targeted therapy in renal cell carcinoma. World J Urol (Epub ahead of print)","DOI":"10.1007\/s00345-013-1074-7"},{"key":"3253_CR49","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.ejca.2006.04.023","volume":"42","author":"Lamuraglia","year":"2006","unstructured":"Lamuraglia M, Escudier B, Chami L et al (2006) To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 42:2472\u20132479","journal-title":"Eur J Cancer"},{"key":"3253_CR50","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1158\/1078-0432.CCR-09-2175","volume":"16","author":"Lassau","year":"2010","unstructured":"Lassau N, Koscielny S, Albiges L et al (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16:1216\u20131225","journal-title":"Clin Cancer Res"},{"key":"3253_CR51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1148\/radiol.10091362","volume":"256","author":"Fournier","year":"2010","unstructured":"Fournier LS, Oudard S, Thiam R et al (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256:511\u2013518","journal-title":"Radiology"},{"key":"3253_CR52","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/JCO.2007.15.5655","volume":"26","author":"Hahn","year":"2008","unstructured":"Hahn OM, Yang C, Medved M et al (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26:4572\u20134578","journal-title":"J Clin Oncol"},{"key":"3253_CR53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1102\/1470-7330.2011.0032","volume":"11","author":"Desar","year":"2011","unstructured":"Desar IM, ter Voert EG, Hambrock T et al (2011) Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging 11:259\u2013265","journal-title":"Cancer Imaging"},{"key":"3253_CR54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/cbr.2008.0527","volume":"24","author":"Vercellino","year":"2009","unstructured":"Vercellino L, Bousquet G, Baillet G et al (2009) 18F-FDG-PET\/CT imaging for an early response assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm 24:137\u2013144","journal-title":"Cancer Biother Radiopharm"},{"key":"3253_CR55","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1158\/1078-0432.CCR-10-3309","volume":"17","author":"Kayani","year":"2011","unstructured":"Kayani I, Avril N, Bomanji J et al (2011) Sequential FDG-PET\/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17:6021\u20136028","journal-title":"Clin Cancer Res"},{"key":"3253_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000318985","volume":"85","author":"Heidenreich","year":"2010","unstructured":"Heidenreich A, Albers P, Classen J et al (2010) Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int 85:1\u201310","journal-title":"Urol Int"},{"key":"3253_CR57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","volume":"13","author":"Choi","year":"2008","unstructured":"Choi H (2008) Response evaluation of gastrointestinal stromal tumors. Oncologist 13(Suppl 2):4\u20137","journal-title":"Oncologist"},{"key":"3253_CR58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2463\/mrms.6.147","volume":"6","author":"Nakanishi","year":"2007","unstructured":"Nakanishi K, Kobayashi M, Nakaguchi K et al (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 6:147\u2013155","journal-title":"Magn Reson Med Sci"},{"key":"3253_CR59","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00330-006-0361-8","volume":"17","author":"Schmidt","year":"2007","unstructured":"Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939\u2013949","journal-title":"Eur Radiol"},{"key":"3253_CR60","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","volume":"97","author":"Sternberg","year":"2003","unstructured":"Sternberg CN, Pansadoro V, Calabro F et al (2003) Can patient selection for bladder preservation be based on response nto chemotherapy? Cancer 97:1644\u20131652","journal-title":"Cancer"},{"key":"3253_CR61","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2008.20.6722","volume":"27","author":"Kibel","year":"2009","unstructured":"Kibel AS, Dehdashti F, Katz MD et al (2009) Prospective study of 18F fluorodeoxyglucose positron emission tomography\/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 27:4314\u20134320","journal-title":"J Clin Oncol"},{"key":"3253_CR62","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.juro.2012.11.009","volume":"189","author":"Mertens","year":"2013","unstructured":"Mertens LS, Fioole-Bruining A, Rhijn BWG van et al (2013) FDG-positron emission tomography\/computerized tomography for monitoring the response of pelvic lymph node metastases to neoadjuvant chemotherapy for bladder cancer. J Urol 189:1687\u20131691","journal-title":"J Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-013-3253-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-013-3253-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-013-3253-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T02:53:46Z","timestamp":1564628026000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-013-3253-y"}},"subtitle":["Rationale bildgebende Diagnostik"],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":62,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["3253"],"URL":"https:\/\/doi.org\/10.1007\/s00120-013-3253-y","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}